Efficacy of 96 weeks adefovir dipivoxil treatment in HBeAg positive chronic hepatitis B patients with various baseline biochemical levels

摘要

Background: Adefovir dipivoxil (ADV) has shown efficacy and safety in a broad range of populations with chronic hepatitis B over 48 to 96 weeks. This study reports the 96-week long-term efficacy data with ADV treatment in nucleoside-naive HBeAg-positive chronic hepatitis B patients with various baseline biochemical levels.